Researchers Develop Low-Cost, Low-Coverage Sequencing Assay to Assess Copy Number | GenomeWeb

By Monica Heger

A sequencing-based assay that assesses copy number could become a low-cost tool to look for cancer biomarkers and assess drug effectiveness, according to researchers now at the Center for Translational Oncology and Immunology in Mainz, Germany.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.